Good evening :)
$
₹
FRACTYL+HEALTH+INC

FRACTYL+HEALTH+INC

GUTS

US
Asset Logo

FRACTYL+HEALTH+INC

GUTS

US
$1.061.38% (-0.01)
$
₹
$1.061.38% (-0.01)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $14.3M the stock is ranked 5563

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

5.06
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-10.56
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Based on 7 analysts reports

Buy
6 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

—

Earnings Growth

—

Rev. Growth

—

Company Profile

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
38.55
38.55
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.16
38.16
1Y Return
3.48%
3.48%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
54.69
54.69
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.44
23.44
1Y Return
1.27%
1.27%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
31.82
31.82
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

Financials

Financials

Income

Balance Sheet

Cash Flow

-45.6
-43.7
9.2
-25.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.030.040.010000000
Net Income-3.32-17.22-23.17-24.97-23.73-27.88-45.60-43.729.21-25.53
Net Profit Margin-10066.66%-40067.44%-165521.42%-832333.33%------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
FRACTYL+HEALTH+INC -5.06-
Abbott Laboratories38.553.572.12
Danaher Corporation38.162.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare GUTS with any stock or ETF
Compare GUTS with any stock or ETF
Comparing from
GUTS
ABT
DHR
Loading...

Frequently asked questions

  1. FRACTYL+HEALTH+INC (GUTS) share price today is $1.06 as of October 26, 2026 at 11:12 PM IST. The stock touched a day high of $1.08 and a day low of $1.02.

  2. FRACTYL+HEALTH+INC stock trades on US under the ticker symbol GUTS.

  3. FRACTYL+HEALTH+INC's market capitalization is $14.32M as of October 26, 2026 at 11:12 PM IST.

  4. FRACTYL+HEALTH+INC's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. FRACTYL+HEALTH+INC's price-to-book (P/B) ratio is 5.06 as of October 26, 2026.

  6. Yes, You can buy FRACTYL+HEALTH+INC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy FRACTYL+HEALTH+INC shares in three steps: 1. Search FRACTYL+HEALTH+INC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since FRACTYL+HEALTH+INC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in FRACTYL+HEALTH+INC (GUTS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 9.3896 shares at the current price of $1.06.

Loading...